Recent Updates
Recently added Catalysts
EPRX Positive Sentiment Score: 70/100

FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Eupraxia Pharmaceuticals Inc. (the " Company ") 201-2067 Cadboro Bay Rd. Victoria, British Columbia Canada, V8R 5G4 Item 2: Date of Material Change

Friday, September 19, 2025 1 min read
Key Takeaway: Eupraxia Pharmaceuticals Inc. has appointed Alex Rothwell as the new Chief Financial Officer, effective immediately. This change comes as Bruce Cousins, the previous CFO, retires but will remain in a consulting role to facilitate a smooth transition. The announcement was made on February 18, 2025, and indicates a potential shift in the company's financial direction while ensuring continued stability during the changeover.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of a new CFO can indicate growth and potential profitability.
  • The outgoing CFO will assist in the transition, ensuring stability.

CONCERNS & RISKS

  • The retirement of the outgoing CFO could signal internal changes or adjustments.

Full Press Release Details

MATERIAL CHANGE REPORT
Eupraxia Pharmaceuticals Inc. (the "Company")
201-2067 Cadboro Bay Rd.
Victoria, British Columbia
A news release announcing the material change was issued on February 18, 2025 through Globe Newswire and a copy was subsequently filed on
On February 18, 2025, the Company announced that it had appointed Alex Rothwell as the Company's new Chief Financial Officer
("CFO"), effective immediately.
On February 18, 2025, the Company announced that it had appointed Alex Rothwell as the Company's new CFO, effective immediately.
Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly
transition of the CFO responsibilities.
For further information, please contact James A. Helliwell, Chief Executive Officer of the Company at 250-590-3968.

Frequently Asked Questions

What announcement was made by Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals announced the appointment of Alex Rothwell as CFO.

When was the CFO appointment announcement issued?

The announcement regarding the new CFO was made on February 18, 2025.

Who is the outgoing CFO of Eupraxia Pharmaceuticals?

Bruce Cousins is the outgoing CFO who is retiring.

What is Bruce Cousins' role after retiring?

Bruce Cousins will act as a consultant during the transition period.

Who to contact for more information about the changes?

James A. Helliwell, the CEO, can be contacted for more information.

Tags: EPRX Viatris Investor Conferences Healthcare Eupraxia Pharmaceuticals financial leadership Alex Rothwell CFO appointment
Last updated: Sep 19, 2025